Olema Oncology宣布与辉瑞达成新临床试验协议,将Palazestrant与Atirmociclib联合用于ER+/HER2-转移性乳腺癌治疗

美股速递
Sep 02, 2025

Olema Oncology宣布与辉瑞达成新临床试验协议,将Palazestrant与Atirmociclib联合用于ER+/HER2-转移性乳腺癌治疗。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10